← All trials
NCT02195986
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Dec 1, 2014
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 366
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- MylanLead sponsor
- Comprehensive Clinical Trials, LLCOverall official - principal investigator
- Meridien ResearchOverall official - principal investigator
- Visions Clinical ResearchOverall official - principal investigator
- Horizons Clinical Research Center, LLCOverall official - principal investigator
- Lawrence OB/GYN Clinical Research, LLCOverall official - principal investigator
- Physician Care Clinical Research LLCOverall official - principal investigator
- Health Awareness, IncOverall official - principal investigator
- Veritas Research., Corp.Overall official - principal investigator
- South Coast Research Center, Inc.Overall official - principal investigator
- OB-GYN Associates of Mid FloridaOverall official - principal investigator
- MCB Clinical Research Centers, LLCOverall official - principal investigator
- Sunrise Medical Research, Inc.Overall official - principal investigator
- AXIS Clinicals LimitedOverall official - principal investigator
- Northern California Research CorpOverall official - principal investigator
- MylanStudy chair
- Arizona Research AssociatesOverall official - principal investigator
- MylanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.